Infection Immunology, Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Institute of Pathology, University of Bern, Bern, Switzerland.
Cancer Res. 2021 Jun 1;81(11):2970-2982. doi: 10.1158/0008-5472.CAN-20-2133. Epub 2021 Mar 16.
Colorectal cancer is one of the most frequent malignancies worldwide. Despite considerable progress in early detection and treatment, there is still an unmet need for novel antitumor therapies, particularly in advanced colorectal cancer. Regulatory T cells (Treg) are increased in the peripheral blood and tumor tissue of patients with colorectal cancer. Recently, transient ablation of tumor-associated Tregs was shown to foster CD8 T-cell-mediated antitumoral immunity in murine colorectal cancer models. However, before considering therapies on targeting Tregs in patients with cancer, detailed knowledge of the phenotype and features of tumor-associated Tregs is indispensable. Here, we demonstrate in a murine model of inflammation-induced colorectal cancer that tumor-associated Tregs are mainly of thymic origin and equipped with a specific set of molecules strongly associated with enhanced migratory properties. Particularly, a dense infiltration of Tregs in mouse and human colorectal cancer lesions correlated with increased expression of the orphan chemoattractant receptor GPR15 on these cells. Comprehensive gene expression analysis revealed that tumor-associated GPR15 Tregs have a Th17-like phenotype, thereby producing IL17 and TNFα. Gpr15 deficiency repressed Treg infiltration in colorectal cancer, which paved the way for enhanced antitumoral CD8 T-cell immunity and reduced tumorigenesis. In conclusion, GPR15 represents a promising novel target for modifying T-cell-mediated antitumoral immunity in colorectal cancer. SIGNIFICANCE: The G protein-coupled receptor 15, an unconventional chemokine receptor, directs Tregs into the colon, thereby modifying the tumor microenvironment and promoting intestinal tumorigenesis..
结直肠癌是全球最常见的恶性肿瘤之一。尽管在早期检测和治疗方面取得了相当大的进展,但仍需要新型抗肿瘤疗法,特别是在晚期结直肠癌中。调节性 T 细胞(Treg)在结直肠癌患者的外周血和肿瘤组织中增加。最近,研究表明,短暂消融肿瘤相关的 Treg 可促进 CD8 T 细胞介导的结直肠癌细胞抗肿瘤免疫。然而,在考虑针对癌症患者的 Treg 治疗之前,详细了解肿瘤相关 Treg 的表型和特征是必不可少的。在这里,我们在炎症诱导的结直肠癌小鼠模型中证明,肿瘤相关的 Treg 主要来源于胸腺,并具有一套与增强迁移特性密切相关的特定分子。特别是,Treg 在小鼠和人类结直肠癌病变中的密集浸润与这些细胞上孤儿趋化因子受体 GPR15 的表达增加相关。综合基因表达分析显示,肿瘤相关的 GPR15 Treg 具有 Th17 样表型,从而产生 IL17 和 TNFα。Gpr15 缺陷抑制了结直肠癌中的 Treg 浸润,为增强抗肿瘤 CD8 T 细胞免疫和减少肿瘤发生铺平了道路。总之,GPR15 代表了一种有前途的新型靶点,可用于修饰结直肠癌中的 T 细胞介导的抗肿瘤免疫。意义:G 蛋白偶联受体 15,一种非传统的趋化因子受体,将 Treg 导向结肠,从而改变肿瘤微环境并促进肠道肿瘤发生。